Human VEGF-C Quantikine ELISA Kit
| Name | Human VEGF-C Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DVEC00 |
| Category | ELISA Kit |
| Prices | $519.00 |
| Sizes | 1 kit |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (50 uL), Serum (10 uL), EDTA Plasma (50 uL), Platelet-poor Plasma (50 uL), Heparin Plasma (50 uL), Saliva (50 uL) |
| Sensitivity | 48.4 pg/mL |
| Range | 109.0 - 7,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Platelet-poor Plasma, Heparin Plasma, Saliva) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human VEGF-C Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human VEGF-C in cell culture supernates, serum, plasma, and saliva |
| Gene | VEGFC |
| Supplier Page | Shop |
Product images
Product References
Human neural stem cell-induced endothelial morphogenesis requires - Human neural stem cell-induced endothelial morphogenesis requires
Chou CH, Modo M. Sci Rep. 2016 Jul 4;6:29029.
The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis. - The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.
Tutunea-Fatan E, Majumder M, Xin X, Lala PK. Mol Cancer. 2015 Feb 10;14:35.
Identification of tumour-reactive lymphatic endothelial cells capable of inducing - Identification of tumour-reactive lymphatic endothelial cells capable of inducing
Tokumoto MW, Tanaka H, Tauchi Y, Kasashima H, Kurata K, Yashiro M, Sakurai K, Toyokawa T, Kubo N, Amano R, Kimura K, Muguruma K, Maeda K, Ohira M, Hirakawa K. Br J Cancer. 2015 Sep 29;113(7):1046-54.
Filarial excretory-secretory products induce human monocytes to produce - Filarial excretory-secretory products induce human monocytes to produce
Weinkopff T, Mackenzie C, Eversole R, Lammie PJ. PLoS Negl Trop Dis. 2014 Jul 10;8(7):e2893.
Vascular endothelial growth factor c promotes ovarian carcinoma progression - Vascular endothelial growth factor c promotes ovarian carcinoma progression
Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, Jurgensmeier JM, Giavazzi R, Belotti D. Am J Pathol. 2014 Apr;184(4):1050-61.
Telmisartan, a possible PPAR-delta agonist, reduces TNF-alpha-stimulated VEGF-C - Telmisartan, a possible PPAR-delta agonist, reduces TNF-alpha-stimulated VEGF-C
Kimura H, Mikami D, Kamiyama K, Sugimoto H, Kasuno K, Takahashi N, Yoshida H, Iwano M. Biochem Biophys Res Commun. 2014 Nov 14;454(2):320-7. doi:
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian - Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian
Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Yla-Herttuala S, Anttila M. BMC Cancer. 2014 Sep 23;14:696.
KML001 inhibits cell proliferation and invasion in pancreatic cancer cells - KML001 inhibits cell proliferation and invasion in pancreatic cancer cells
Yang MH, Kim HT, Lee KT, Yang S, Lee JK, Lee KH, Rhee JC. Anticancer Res. 2014 Jul;34(7):3469-74.
Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary - Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary
Braicu EI, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J. Cytokine. 2013 Mar;61(3):755-8.
Long-term survival and biomarker correlates of tasquinimod efficacy in a - Long-term survival and biomarker correlates of tasquinimod efficacy in a
Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle O, Forsberg G, Carducci MA, Pili R. Clin Cancer Res. 2013 Dec 15;19(24):6891-901.